NYSE American - Delayed Quote USD

NeurAxis, Inc. (NRXS)

3.1600 0.0000 (0.00%)
At close: May 24 at 3:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,301.5740
2,460.0490
2,684.7350
2,721.2860
1,930.2280
Cost of Revenue
282.5260
303.3450
297.0600
467.6560
481.0890
Gross Profit
2,019.0480
2,156.7040
2,387.6750
2,253.6300
1,449.1390
Operating Expense
9,619.3890
8,821.1990
5,759.9130
5,223.6640
5,569.8770
Operating Income
-7,600.3410
-6,664.4950
-3,372.2380
-2,970.0340
-4,120.7380
Net Non Operating Interest Income Expense
-2,812.7610
-5,360.8100
-2,739.8170
-36.9280
-75.6740
Other Income Expense
-4,160.8220
-2,601.3780
1,331.9940
-21.0700
470.2630
Pretax Income
-14,573.9240
-14,626.6830
-4,780.0610
-3,028.0320
-3,726.1490
Net Income Common Stockholders
-14,573.9240
-14,626.6830
-5,544.9540
-3,776.8640
-4,315.3050
Diluted NI Available to Com Stockholders
-14,573.9240
-14,626.6830
-5,544.9540
-3,776.8640
-4,315.3050
Basic EPS
-2.24
-4.50
-0.90
-0.62
-0.80
Diluted EPS
-2.24
-4.50
-0.90
-0.62
-0.80
Basic Average Shares
6,594.8970
3,252.3280
6,139.9730
6,139.9730
5,382.5490
Diluted Average Shares
6,594.8970
3,252.3280
8,412.2450
6,139.9730
5,382.5490
Total Operating Income as Reported
-7,600.3410
-6,664.4950
-3,372.2380
-2,970.0340
-4,120.7380
Total Expenses
9,901.9150
9,124.5440
6,056.9730
5,691.3200
6,050.9660
Net Income from Continuing & Discontinued Operation
-14,573.9240
-14,626.6830
-4,780.0610
-3,028.0320
-3,726.1490
Normalized Income
-10,402.8820
-12,020.5270
-6,100.0990
-2,998.6900
-3,948.0600
Interest Income
--
--
--
--
0.0370
Interest Expense
2,581.9370
5,358.0380
417.6010
36.9280
75.7110
Net Interest Income
-2,812.7610
-5,360.8100
-2,739.8170
-36.9280
-75.6740
EBIT
-11,991.9870
-9,268.6450
-4,362.4600
-2,991.1040
-3,650.4380
EBITDA
-11,950.3740
-9,227.9200
-4,325.3270
-2,954.3960
-3,614.6510
Reconciled Cost of Revenue
282.5260
303.3450
297.0600
467.6560
481.0890
Reconciled Depreciation
41.6130
40.7250
37.1330
36.7080
35.7870
Net Income from Continuing Operation Net Minority Interest
-14,573.9240
-14,626.6830
-4,780.0610
-3,028.0320
-3,726.1490
Total Unusual Items Excluding Goodwill
-4,171.0420
-2,606.1560
1,320.0380
-29.3420
221.9110
Total Unusual Items
-4,171.0420
-2,606.1560
1,320.0380
-29.3420
221.9110
Normalized EBITDA
-7,779.3320
-6,621.7640
-5,645.3650
-2,925.0540
-3,836.5620
12/31/2020 - 8/9/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NRSNW NeuroSense Therapeutics Ltd.
0.1300
-23.53%
 
XP0.BE Xenon Pharmaceuticals Inc
35.40
0.00%
 
XP0.SG Xenon Pharmaceuticals Inc
35.00
+0.57%
 
IDIAz.XC
 
CTCX Carmell Corporation
2.5300
-1.56%
 
QLGN Qualigen Therapeutics, Inc.
0.2820
-7.54%
 
ANEB Anebulo Pharmaceuticals, Inc.
2.0800
-0.95%
 
FRES Fresh2 Group Limited
0.4000
+4.99%
 
KA Kineta, Inc.
0.4690
-1.30%
 
ORGS Orgenesis Inc.
0.4602
-8.36%